Dimitrios Moris1, Timothy M Pawlik2. 1. Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center and James Cancer Hospital and Solove Research Institute, Columbus, Ohio. Electronic address: dimmoris@yahoo.com. 2. Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center and James Cancer Hospital and Solove Research Institute, Columbus, Ohio.
Abstract
BACKGROUND: Precision Medicine Initiative is a new research effort aiming to offer personalized treatment in many diseases, including cancer. The aim of the present article is to offer novel insights about the role of personalized treatment in patients with colorectal liver metastases (CRLM). METHODS: A review of the literature regarding personalized medicine and colorectal liver metastases was performed mainly in the MEDLINE/PubMed database. RESULTS: Surgical resection remains the only hope for cure of CRLM. Improved surgical strategies to optimize remnant liver volume are recently introduced and gaining ground. Following resection of CRLM scoring systems have been developed by combining certain preoperative factors such as microsatellite instability KRAS expression and sensitivity to immunotherapy with Programmed Death-1 inhibitor. CONCLUSIONS: Multidisciplinary management of patients with CRLM has markedly contributed to increased survival. While the last several decades have been characterized by these important developments, future advances for patients with CRLM will depend on a better understanding of genomics and molecular biology to facilitate characterization of a specific tumor "identity" so that individualized treatment for each CRLM patient becomes the rule, and not the exception.
BACKGROUND: Precision Medicine Initiative is a new research effort aiming to offer personalized treatment in many diseases, including cancer. The aim of the present article is to offer novel insights about the role of personalized treatment in patients with colorectal liver metastases (CRLM). METHODS: A review of the literature regarding personalized medicine and colorectal liver metastases was performed mainly in the MEDLINE/PubMed database. RESULTS: Surgical resection remains the only hope for cure of CRLM. Improved surgical strategies to optimize remnant liver volume are recently introduced and gaining ground. Following resection of CRLM scoring systems have been developed by combining certain preoperative factors such as microsatellite instability KRAS expression and sensitivity to immunotherapy with Programmed Death-1 inhibitor. CONCLUSIONS: Multidisciplinary management of patients with CRLM has markedly contributed to increased survival. While the last several decades have been characterized by these important developments, future advances for patients with CRLM will depend on a better understanding of genomics and molecular biology to facilitate characterization of a specific tumor "identity" so that individualized treatment for each CRLM patient becomes the rule, and not the exception.
Authors: Vladislav Treska; Jan Bruha; Vaclav Liska; Jakub Fichtl; Kristyna Prochazkova; Tereza Petrakova; Petr Hosek Journal: In Vivo Date: 2020 Sep-Oct Impact factor: 2.155
Authors: Mark Lawler; Deborah Alsina; Richard A Adams; Annie S Anderson; Gina Brown; Nicola S Fearnhead; Stephen W Fenwick; Stephen P Halloran; Daniel Hochhauser; Mark A Hull; Viktor H Koelzer; Angus G K McNair; Kevin J Monahan; Inke Näthke; Christine Norton; Marco R Novelli; Robert J C Steele; Anne L Thomas; Lisa M Wilde; Richard H Wilson; Ian Tomlinson Journal: Gut Date: 2018-01 Impact factor: 23.059
Authors: Attila Kovács; Peter Bischoff; Hathal Haddad; György Kovács; Andreas Schaefer; Willi Zhou; Michael Pinkawa Journal: Front Oncol Date: 2021-04-01 Impact factor: 6.244
Authors: Ian S Reynolds; Paul M Cromwell; Éanna J Ryan; Erinn McGrath; Rory Kennelly; Ronan Ryan; Niall Swan; Kieran Sheahan; Des C Winter; Emir Hoti Journal: Front Oncol Date: 2022-02-21 Impact factor: 6.244
Authors: Joost Hof; Lydia Visser; Diederik J Höppener; Pieter M H Nierop; Miente M Terpstra; Annette S H Gouw; Dirk J Grünhagen; Cornelis Verhoef; Rolf H Sijmons; Koert P de Jong; Klaas Kok Journal: Front Oncol Date: 2020-03-05 Impact factor: 6.244